Patient characteristics
| Characteristics | Values* |
| Age, median (range) | 55 (39–74) |
| Gender | |
| Male | 23 (74.2) |
| Female | 8 (25.8) |
| Previous gastrectomy | |
| Yes | 5 (16.1) |
| No | 26 (83.9) |
| Primary tumor site | |
| Cardia | 1 (3.2) |
| Body | 13 (41.9) |
| Angle | 13 (41.9) |
| Antrum | 4 (12.9) |
| Metastatic site | |
| Liver | 10 (32.3) |
| Lung | 2 (6.5) |
| Lymph nodes | 28 (90.3) |
| Peritoneum | 18 (58.1) |
| Prior lines of chemotherapy | |
| 1 regimen | 15 (48.4) |
| 2 regimens | 11 (35.5) |
| ≥3 regimens | 5 (16.1) |
| Prior anti-PD1 therapy | 2 (6.5) |
| Prior HER-2 directed therapy | 2 (6.5) |
| Pathology | |
| Poorly differentiated | 13 (41.9) |
| Moderately differentiated | 12 (38.7) |
| Signet ring cell carcinoma | 6 (19.4) |
| HER2 positive | 2 (6.5) |
| EBV positivity | |
| Positive | 5 (16.1) |
| Negative | 23 (74.2) |
| Not available | 3 (9.7) |
| PD-L1 (22C3) | |
| Positive | 24 (77.4) |
| Negative | 5 (16.1) |
| Not available | 2 (6.5) |
| ATM IHC | |
| Loss | 8 (25.8) |
| Intact | 21 (67.7) |
| Not available | 2 (6.5) |
| Mismatch repair | |
| Microsatellite stable | 30 (96.8) |
| Microsatellite instability-high | 1 (3.2) |
*Number (%) if not specified.
ATM, ataxia telangiectasia mutated; EBV, Epstein-Barr virus; IHC, immunohistochemistry.